Dr. Ji Li has about 25 years of business development, R&D and investment experience in the biopharmaceutical sector. Ji is currently President, Chief Strategy Officer, and member of the Board of Directors at AffaMed Therapeutics, a leading clinical stage biotech in China with focus in neuroscience and ophthamology. Prior to AffaMed, Ji served as Venture Partner at Lilly Asia Ventures (LAV). Before that, Ji was Executive VP and Global Head of BD at BeiGene where he is responsible for the company’s partnering activities worldwide, including leading the landmark strategic transaction with Celgene that has transformed BeiGene into a fully integrated biopharmaceutical company. Prior to BeiGene, Ji served as VP of BD&L at Merck, where he led the group that was responsible for BD activities of all late-stage inbound and outbound partnering opportunities globally. Prior to Merck, Ji was Executive Licensing Director, External R&D at Amgen where he led the company’s product search and evaluation BD team. Ji obtained his BS in Pharmacology from Shanghai Medical University and PhD in Neuroscience from Mount Sinai School of Medicine in New York.